Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



A Mini-Pfizer in the Making

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Bristol-Myers Squibb (NYSE: BMY  ) looks like its setting itself up to be the next Pfizer (NYSE: PFE  ) .

No, not the patent-cliff monster Pfizer has become. The Pfizer before it bit off more than it could chew with Wyeth (NYSE: WYE  ) . The previously cash-rich Pfizer.

For instance, Bristol-Myers brought in $895 million this quarter when Eli Lilly (NYSE: LLY  ) paid it for the 17% of ImClone that it owned, which brought its war chest up to about $8 billion.

OK, maybe Bristol-Myers is only at mini-Pfizer stage now; before the Wyeth announcement, Pfizer had about $26 billion in cash and equivalents. But Bristol isn't done saving for a rainy day. It'll also get some of the proceeds when it spins off its Mead Johnson Nutrition business in the first half of this year -- a 7% year-over-year increase in revenue last year by the baby formula business should help secure a good price for the IPO.

And of course the company is adding to its cash reserves the old-fashioned way -- by earning it. Bristol-Myers didn't release a cash flow statement with its earnings yesterday -- we'll have to wait for the 10-K -- but the 12 months through September resulted in more than $3 billion in free cash flow. And the company has a plan to increase operating cash flow by $1 billion by the end of next year.

Earnings, which came in up 37% for the year after adjustments, are all fine and dandy, but it's cash that's king and cash is what Fools should be paying attention to. The green stuff pays for the pipeline additions like Bristol-Myers' recent deals with Exelixis (Nasdaq: EXEL  ) and ZymoGenetics (Nasdaq: ZGEN  ) , and it pays investors' dividends, as well.

Let's just hope that not getting in a bidding war with Eli Lilly for ImClone is a sign that Bristol-Myers' management is a better value investor than Pfizer's management.

Pfizer is both an Income Investor and an Inside Value selection. Exelixis is a Rule Breakers pick and the Fool owns shares of Pfizer and Exelixis. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., would work a pot shot about Pfizer into every article he wrote if his editor would let him. He doesn't own shares of any company mentioned in this article. The Fool's disclosure policy votes for Wi-Phi as the new company name.

Read/Post Comments (0) | Recommend This Article (13)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 819125, ~/Articles/ArticleHandler.aspx, 10/28/2016 8:46:26 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 11 hours ago Sponsored by:
DOW 18,169.68 -29.65 0.00%
S&P 500 2,133.04 -6.39 0.00%
NASD 5,215.97 -34.29 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/27/2016 4:00 PM
BMY $51.96 Up +2.67 +0.00%
Bristol-Myers Squi… CAPS Rating: ****
EXEL $10.92 Down -0.26 +0.00%
Exelixis CAPS Rating: ****
LLY $76.16 Down -0.60 +0.00%
Eli Lilly and Co. CAPS Rating: ***
PFE $32.48 Up +0.08 +0.00%
Pfizer CAPS Rating: ****
WYE.DL $0.00 Down +0.00 +0.00%
Wyeth CAPS Rating: ***
ZGEN.DL $0.00 Down +0.00 +0.00%
ZymoGenetics, Inc. CAPS Rating: ***